CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Core Insights - CervoMed Inc. is presenting updated data on neflamapimod, a treatment for Dementia with Lewy Bodies (DLB), at the upcoming CTAD Conference [1][2] - The Phase 2b RewinD-LB trial results will be highlighted, showcasing the drug's effects on neurodegeneration biomarkers [3][6] - DLB is a significant health concern, being the second most common progressive dementia after Alzheimer's, with no approved treatments available [4][9] Company Overview - CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders, with neflamapimod as its lead candidate [10] - The company plans to initiate a pivotal Phase 3 trial for neflamapimod in DLB patients in the second half of 2026 [10] Clinical Trial Details - The RewinD-LB trial was a randomized, double-blind, placebo-controlled study involving 159 participants, assessing the efficacy of neflamapimod [6][7] - The trial's primary endpoint was the change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB), with secondary endpoints including various cognitive assessments [6] Drug Mechanism and Efficacy - Neflamapimod is an investigational small-molecule drug that inhibits a key enzyme involved in neuroinflammation, potentially reversing synaptic dysfunction [11][12] - Previous trials have shown that neflamapimod significantly improved dementia severity and functional mobility in DLB patients [12]